Abelacimab is under clinical development by Anthos Therapeutics and currently in Phase III for Atrial Fibrillation. According to GlobalData, Phase III drugs for Atrial Fibrillation have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Abelacimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Abelacimab is under development for the prevention of arterial and venous thrombosis, venous thromboembolism (VTE), pulmonary embolism, deep vein thrombosis, inflammation and stroke and systemic embolism in patients with atrial fibrillation. The therapeutic candidate is an anti-FXI monoclonal antibody and is a new molecular entity. It acts by targeting coagulation factor XI. It is administered through subcutaneous and intravenous routes.
Anthos Therapeutics overview
Anthos Therapeutics is a healthcare company engaged in the research and development of genetically and pharmacologically validated therapies for cardiovascular and metabolic (CVM) diseases. The company is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of Abelacimab’s drug-specific PTSR and LoA scores, buy the report here.